1984
DOI: 10.1007/bf00175379
|View full text |Cite
|
Sign up to set email alerts
|

Phase I study with 4′ -deoxydoxorubicin

Abstract: 4'-Deoxydoxorubicin (dxDx), a new doxorubicin analogue, was administered intravenously on a 3-week schedule to 73 patients affected by advanced malignant neoplasms. Sixty-five patients, treated with eight dose levels ranging from 10 to 45 mg/m2, were evaluable. The dose-limiting toxicity was myelosuppression, mainly leukopenia. About one third of the patients complained of vomiting which was almost always mild. Minimal hair loss was also documented in about 40% of patients. No hepatic or renal toxicity was obs… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
11
0

Year Published

1984
1984
2010
2010

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 27 publications
(13 citation statements)
references
References 9 publications
2
11
0
Order By: Relevance
“…These results agree with the observation of a disappearance of nuclear fluorescence in colon cancer cells cultivated for 1 day or longer in the presence of DX (Chauffert et al, 1984 (Hill et al, 1985). Some anthracyclines showed a low RI like 4-demethoxy-DNR (RI=3) and 4'-deoxy-DX (RI=30) and these data too are in accordance with experimental and clinical trials (Ferrari et al, 1984;Kaplan et al, 1984;Hill et al, 1985). 4'-Deoxy-4'-iodio-DX was cytotoxic on B16VDXR to the same extent as that on B16V.…”
Section: Discussionsupporting
confidence: 90%
See 1 more Smart Citation
“…These results agree with the observation of a disappearance of nuclear fluorescence in colon cancer cells cultivated for 1 day or longer in the presence of DX (Chauffert et al, 1984 (Hill et al, 1985). Some anthracyclines showed a low RI like 4-demethoxy-DNR (RI=3) and 4'-deoxy-DX (RI=30) and these data too are in accordance with experimental and clinical trials (Ferrari et al, 1984;Kaplan et al, 1984;Hill et al, 1985). 4'-Deoxy-4'-iodio-DX was cytotoxic on B16VDXR to the same extent as that on B16V.…”
Section: Discussionsupporting
confidence: 90%
“…Pleiotropic drug-resistance has been reported for many different cell lines (Kaye & Merry, 1985). We tested, therefore, whether B16VDXR cells were sensitive to the cytotoxic action of other anthracyclines and of anticancer drugs having (Ferrari et al, 1984;Kaplan et al, 1984;Holdener et al, 1985), and 4'-deoxy-4'-iodio-DX, because it has been shown to be active on the DX-resistant P388 cell line (Facchinetti et al, 1984). VCR, a typical DX cross-resistant drug (Wilkoff & Dulmadge, 1978), and cis-DDP, a non DX crossresistant drug (Seeber et al, 1982), were also tested.…”
Section: Stability Of Resistancementioning
confidence: 99%
“…The weekly administration schedule appeared, in addition, particularly promising on the basis of the apparent schedule dependency of the antitumor activity observed in some experimental models (2). In agreement with the data of the single dose intermittent schedule (7)(8)(9), this Phase I trial shows that leukopenia is the major dose-limiting toxic effect of 4'-deoxydoxorubicin, with thrombocytopenia almost exclusively occurring in patients with a WBC < 1500//d. The narrow ranges of values and times of nadirs reported in this study confirm the previous suggestion of a well predictable hematologic toxicity, with prior chemotherapy and performance status as important factors affecting the hematologic tolerance.…”
Section: Discussionsupporting
confidence: 67%
“…The maximum tolerated dosage of DxDx given as a bolus injection on an every 3-week schedule was 36 Phase I trials involving adults [6,7]. In our study, a dosage of 43.2 mg/m 2 was found to be intolerable due to significant and prolonged myelosuppression.…”
Section: Discussionmentioning
confidence: 77%